Combined Shareholders’ Meeting of IPSEN S.A. held on 28 May 2019
May 28 2019 - 1:00PM
Business Wire
All the resolutions submitted to the
Shareholder’s vote have been approved
Regulatory News:
The Combined Shareholders’ Meeting of Ipsen S.A. (Euronext: IPN;
ADR: IPSEY), chaired by Marc de Garidel, Chairman of the Board, was
held today, in the presence of the members of the Board of
Directors and the Group’s Executive Leadership Team.
The Shareholders’ Meeting approved all the resolutions submitted
by the Board of Directors and in particular the distribution of a
dividend of €1.00 per share to be paid on 4 June 2019 (ex-date 31
May 2019).
The Shareholders’ Meeting also approved the renewal of Marc de
Garidel, Henri Beaufour and Michèle Ollier as directors for a term
of office of 4 years.
The Board of Directors held after the Shareholders’ Meeting also
reappointed Marc de Garidel as Chairman of the Board for the
duration of his term of office as director.
Following this Shareholders’ Meeting, the Board of Directors is
still comprised of 13 members, five of whom are women, four are
independent directors and a director representing the
employees.
During the Meeting, David Meek, Chief Executive Officer, and
Aymeric Le Chatelier, Executive Vice President, Chief Financial
Officer, focused on the group strategy, highlights and financial
results for 2018, confirmed the objectives and guidance for 2019
and also provided financial outlook for 2022.
About IpsenIpsen is a global specialty-driven
biopharmaceutical group focused on innovation and Specialty Care.
The group develops and commercializes innovative medicines in three
key therapeutic areas - Oncology, Neuroscience and Rare Diseases.
Its commitment to Oncology is exemplified through its growing
portfolio of key therapies for prostate cancer, neuroendocrine
tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has
a wellestablished Consumer Healthcare business. With total sales
over €2.2 billion in 2018, Ipsen sells more than 20 drugs in over
115 countries, with a direct commercial presence in more than 30
countries. Ipsen's R&D is focused on its innovative and
differentiated technological platforms located in the heart of the
leading biotechnological and life sciences hubs (Paris-Saclay,
France; Oxford, UK; Cambridge, US). The Group has about 5,700
employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and
in the United States through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information on
Ipsen, visit www.ipsen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190528005354/en/
MediaChristian MarcouxSenior Vice President,
Global Communications+33 (0)1 58 33 67
94christian.marcoux@ipsen.com
Fanny AllaireDirector, Ipsen France Hub, Global
Communications+33 (0)1 58 33 58
96fanny.allaire@ipsen.com
Financial CommunityEugenia LitzVice President,
Investor Relations+44 (0) 1753 627721eugenia.litz@ipsen.com
Myriam KoutchinskyInvestor Relations Manager+33 (0)1 58
33 51 04myriam.koutchinsky@ipsen.com
Ipsen (EU:IPN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ipsen (EU:IPN)
Historical Stock Chart
From Sep 2023 to Sep 2024